AgingResearch.NewsJoin free

Orum Therapeutics

CompanySouth Korea

Orum Therapeutics develops one asset, in phase 1 (ORM-1153 in CD123-expressing hematologic malignancies). Mostly antibody; based in South Korea.

1
Asset
Furthest stage
Phase 1
Raised
$100M
0
Trials
0
Signals

Pipeline

1

  • ORM-1153

    Degrader-antibody conjugate targeting CD123-expressing cancer cells.

    Phase 1, Antibody, CD123-expressing hematologic malignancies, relapsed or refractory acute myeloid leukemia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Funding rounds and grants1
  • Signals1
  • Similar companies2

Intelligence